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ABSTRACT
Background. The recent introduction of biological anti-
cancer therapy has renewed the interest in functional
imaging of tumor-associated angiogenesis (TAA) as a tool
to monitor early therapy response. The present study
evaluated imaging of TAA using P1227, a novel, small
molecular magnetic resonance imaging (MRI) probe tar-
geting avb3 integrin.
Methods. HT29 human colorectal cancers were grown in
athymic mice. Dynamic MRI was performed using a three-
dimensional VIBE sequence up to 110 min after injection
of P1227 or gadolinium–tetraazacyclododecane tetraacetic
acid (Gd–DOTA). Specificity was assessed by using P1227
1 h after intravenous administration of the avb3 inhibitor
cilengitide. Regions of interest were drawn encompassing
the tumor rim and normal muscle. Imaging data were
compared with microvessel density and avb3 expression.
Results. Using P1227, specific enhancement of the
angiogenic tumor rim, but not of normal muscle, was
observed, whereas Gd–DOTA enhanced tumor and normal
muscle. After administering cilengitide, enhancement with
P1227, but not with DOTA, was significantly suppressed
during the first 20 min. When using P1227, a significant
correlation was observed between normalized enhancement
of the tumor rim and immunohistochemical avb3 integrin
expression.
Conclusions. Molecular MRI using a small monogadoli-
nated tracer targeting avb3 integrin and moderate magnetic
field strength holds promise in assessing colorectal TAA.
Early assessment of response to cytotoxic therapy is an
area of intense investigation. Indeed, the ability to dem-
onstrate activity early in the course of therapy not only
allows to predict an individual patient’s prognosis but also
to tailor the therapeutic strategy by timely discontinuation
of inactive regimens. Moreover, early imaging of tumor
response is a valuable tool in preclinical and early phase
clinical drug development.
Changes in the physical dimension of a solid tumor,
which underly the traditional RECIST criteria, often occur
late in the course of therapy.1 Also, as exemplified by
molecular therapy of gastrointestinal stromal tumors, sig-
nificant tumor response can occur without any
accompanying change in tumor dimension.2 Early icono-
graphic assessment of tumor response is not (only) based
upon morphological properties, but on functional proper-
ties of the neoplastic tissue. Research for other valuable
early imaging biomarkers is currently ongoing. Since the
introduction of agents targeting tumor angiogenesis,
increasing efforts have been invested in functional imaging
of the neoplastic vascular bed. Importantly, it has been
shown that the earliest functional change in response to
anti-angiogenic therapy is ‘microvessel normalization’, i.e.
the return from a grossly distorted anatomy and function to
more physiological microvascular properties.3 One of the
hallmarks of this process is a decrease in microvascular
permeability. We recently showed that dynamic contrast-
enhanced (DCE) magnetic resonance imaging (MRI)
incorporating mathematical modeling allows to quantify
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these early changes in microvessel permeability as well as
tumor perfusion.4,5
Although of interest, these parameters remain indirect
estimators of tumor angiogenesis. Direct, specific imaging
requires probes directed against moieties expressed on the
proliferating endothelial cell (EC) surface. A potential target
is avb3 integrin, which is selectively expressed on activated
EC during migration through the basement membrane in the
angiogenic process.6,7 This protein is not upregulated on
quiescent EC.8 Here, we studied a novel avb3 integrin-
directed molecular MRI tracer (P1227) as a tool to visualize
tumor angiogenesis in a colorectal xenograft model.
METHODS
Animals and Tumor Model
Colorectal cancer xenografts (HT29) were subcutane-
ously grown in the hind leg of nude mice (athymic nu/nu,
Harlan Laboratories, The Netherlands). Animals were
housed separately in plastic cages with free access to tap
water and standard pellet food. When tumors reached a size
of 0.2–0.3 cm3 (after 8–10 days), MRI imaging was per-
formed. The protocol was approved by the local Animal
Research Institutional Review Board.
MR Imaging Protocol
Dynamic MR image acquisition was performed on a
MAGNETOM Symphony 1.5 T clinical scanner (Siemens
Healthcare, Brussels, Belgium) using a wrist coil (diameter
10 cm). Imaging was performed using a T1-weighted 3D
VIBE sequence (FOV 180 9 80, matrix size 384 9 384,
voxel dimension 0.5 9 0.5 9 2 mm3, repetition time/echo
time 6.78/2.78 ms, flip angle 12, 60 slices, total duration
per scan 9 min 25 s). Images were acquired at baseline
(before contrast injection) and at regular intervals up to
225 min post-injection. At each timepoint, 60 images were
acquired.
Signal intensity (SI) was measured in blinded, manually
drawn regions of interest (ROIs) encompassing the tumor
rim (outer third of the tumor volume) and normal tissue
(contralateral paravertebral muscle). Normalized enhance-
ment ratio (NER) was calculated as the ratio of enhancement
in the tumor rim over enhancement in normal muscle tissue.
MR Contrast Agent
The contrast agent (CA) (P1227, Guerbet Research,
Paris, France) is a tetraazacyclododecane tetraacetic acid
(DOTA)–gadolinium (Gd) chelate linked to a cyclic argi-
nyl-glycyl-aspartic acid (RGD) peptide (molecular weight
[MW] = 1297 Da). The MW of Gd–DOTA is 560 Da. The
r1 relaxivities of P1227 and Gd–DOTA in plasma at 37 C
and 1.5 T are 8.3 mM-1 s-1 and 3.8 mM-1 s-1, respec-
tively. The binding half maximal inhibitory concentration
of P1227, as tested with enzyme-linked immunosorbent
assay (ELISA) on purified protein, is 3 nM.
Four experimental groups were studied. In the first
group, imaging was performed before and after injection of
P1227 (dose 50 lmol Gd/kg) [n = 15], while in the second
(control) group mice underwent imaging before and after
injection of Gd–DOTA (Dotarem, Guerbet, Paris, France;
dose 100 lmol Gd/kg) [n = 9]. The choice of doubling the
Gd–DOTA dose was based on the much higher relaxivity
of P1227. In the third and fourth groups, imaging with
P1227 (n = 9) or Gd–DOTA (n = 6), respectively, was
performed 1 h after intravenous administration of the avb3
inhibitor cilengitide (dose 1800 mg/m2, Merck KGaA,
Darmstadt, Germany). All products were injected as a rapid
intravenous bolus through the tail vein.
Immunohistochemistry
On the day after MR imaging, tumors were excised and
all mice were sacrificed using cervical dislocation. Half of
the tumor tissue was fixed in 10 % formalin, embedded in
paraffin, and 4 lm thick sections were cut and mounted for
immunohistochemistry. Factor VIII [von Willebrand factor
(vWF), FVIII] immunostaining was used to visualize tumor
microvessels and to calculate microvessel density (MVD).
FVIII staining and MVD calculation were performed as
described earlier.9 The other half of the tumor was snap
frozen in liquid nitrogen, cut in 5 lm-thick sections and
mounted for immunohistochemistry with mouse anti-
human integrin avb3 (US Biological—Immunosource),
similar to the procedure of Schnell et al.10
Western Blot Analysis
Quantification of avb3 integrin protein expression using
western blot, was performed as described by Schnell et al.10
Briefly, snap-frozen tumor tissues were lysed in radioim-
munoprecipitation assay buffer by sonication. Total protein
content was determined with the Bio-Rad DC protein assay
kit (Bio-Rad, Nazareth, Belgium). 50 lg of protein per lane
was mixed with LDS sample buffer (NuPAGE, Invitrogen,
Merelbeke, Belgium). The proteins were denatured by
heating at 70 C for 10 min, separated with 170 V over 1 h
in running buffer (NuPAGE MES, Invitrogen). After that,
proteins were transferred to a nitrocellulose membrane (GE
Healthcare, Buckinghamshire, UK) by a semidry blotting
technique. Next, membranes were blocked over 1 h at room
temperature. The primary antibodies against integrin sub-
units (polyclonal rabbit anti-integrin av subunit AB1930,
dilution 1:5000; and polyclonal rabbit anti-integrin b3
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subunit AB1932, dilution 1:2,000; Chemicon, Millipore,
MA, USA) were incubated overnight at 4 C. Bound anti-
bodies were labeled using a secondary antibody coupled to
alkaline phosphatase (1:2,000 goat anti-rabbit immuno-
globulin) for 1 h. Visualization was performed using
chromogen nitroblue tetrazolium salt and 5-bromo-4-
chloro-3-indolyl phosphate (BCIP/NBT substrate kit,
Invitrogen). Blots were subsequently stripped and reprobed
with monoclonal antibody against b-tubulin (Abcam,
Cambridge, UK; dilution 1:5,000) as an internal control for
protein loading. All blots were digitized by scanning, mean
intensity of each different chain was measured with National
Institutes of Health Image J software and the overall relative
intensity of the different chains of interest was calculated
(mean intensity of chain of interest/mean intensity of
tubulin).
Statistical Analysis
Data are expressed as mean ± standard error of the
mean, or median (interquartile range). Differences were
analyzed using the Student t test or Mann–Whitney rank
sum test where appropriate. Correlations between histology
data and imaging parameters were assessed with Spear-
man’s rank correlation. Statistical analysis was performed
with SigmaStat 11.0 (Systat Software, Richmond, CA,
USA). Results were considered statistically significant
when the probability of a type I error was B5 %.
RESULTS
Signal Enhancement in Tumor and Normal Muscle
After Injection of P1227 Versus Gadolinium–
Tetraazacyclododecane Tetraacetic Acid
Typical enhancement patterns are illustrated in Fig. 1. It
may be appreciated that, as illustrated by the SI histograms,
P1227 specifically enhanced the angiogenic tumor rim
while Gd–DOTA was more homogeneously distributed
towards the center of the tumor. Quantitative evaluation of
the SI changes observed in the tumor rim, entire tumor, and
normal muscle is provided in Fig. 2, where NER are
depicted. NER in the entire tumor appears to be lower than
NER in the tumor rim at each timepoint. When using
P1227, significant enhancement of SI was observed of the
tumor rim (569 ± 15 vs. 472 ± 21; p = 0.004; t test) but
not of normal muscle. However, when using Gd–DOTA,
significant enhancement of SI was noted in both tumor
tissue and normal tissue (614 ± 24 vs. 430 ± 17 in muscle
tissue; p \ 0.001; t test). For both CAs, a peak in nor-
malized enhancement was observed after 5 min. When
using P1227, normalized enhancement after 225 min did
return to baseline. When using Gd–DOTA, however, nor-
malized enhancement at 225 min remained significantly
elevated compared with baseline (precontrast) level
(1,261 ± 0,0818 vs. 1,098 ± 0,122; p = 0.035; t test).
Signal Enhancement in the Tumor Rim
with and without Pretreatment with Cilengitide
To verify whether P1227 binds the target integrin in a
specific way, the inhibitor cilengitide was administered 1 h
before imaging with P1227 (n = 9). The results, expressed
as the ratio of enhancement in the tumor rim over
enhancement in normal tissue, are illustrated in Fig. 3.
Administration of cilengitide before P1227 resulted in a
significantly lower normalized contrast enhancement of the
tumor rim during the first 20 min (p = 0.027; U test).
Between 35 and 60 min, NER was still higher in the P1227
group, but without showing statistically significant differ-
ences compared with the cilengitide pretreated group. After
80–90 min, however, no differences in SI were observed
between both groups. When DOTA was used, however,
pretreatment with cilengitide did not affect tumor rim
enhancement.
Immunohistochemistry and Western Blot
MVD (vWF staining) in all tumors, expressed as the
vascular area fraction, was significantly higher in the tumor
rim compared with the entire tumor [11.25 % (8.7–16.7)
vs. 8.4 % (4.6–12.2); p \ 0.001; U test). Also, the per-
centage of avb3 integrin-expressing endothelium was
12.8 % (10.9–16.9) in the tumor rim versus 11.2 %
(7.9–14.6) in the entire tumor (p = 0.002; U test; Fig. 4b,
c). The results of western blotting confirmed that protein
expression of the av and b3 subunit was significantly higher
in the vascular tumor rim (Fig. 4a, d). Three different
molecular masses can be found in av subunits (at 137 kDa
and, to a much lesser extent, at 27 and 25 kDa) and in b3
subunits (between 90 and 100 kDa, and degradation pro-
ducts at 64 and 52 kDa).10
Correlation of MRI Parameters with Histology Data
Correlation data are summarized in Table 1. When
using Gd–DOTA, no correlation was observed between the
NER in the tumor rim and either avb3 integrin expression
or MVD. However, when using P1227, a statistically sig-
nificant positive correlation was observed between avb3
integrin expression and the NER at 35, 50, and 65 min
post-contrast injection.
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FIG. 1 Enhancement pattern
observed following
administration of P1227 (upper
left) or gadolinium–
tetraazacyclododecane
tetraacetic acid (upper right).
The histograms (lower row)
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DISCUSSION
We have studied the feasibility to probe tumor angio-
genesis using a novel MR CA targeting avb3 integrin. The
integrins are a group of evolutionary conserved heterodi-
meric cell surface receptors which are essential in cell-cell
and cell-matrix interactions.11 Some subtypes are highly
overexpressed on cancer cells: avb3, avb5, and a5b1 play an
important role in mediating tumor angiogenesis, while avb6
and a6b4 have pivotal functions in cell migration and
metastasis.12,13 These interesting properties and their high
level of expression on some tumor types, make the inte-
grins ideal candidates for targeted therapy and imaging
studies. More specifically, integrin avb3 is overexpressed
by some tumor cell types (colorectal cancer, lung cancer,
ovarian cancer, breast cancer, glioblastoma multiforme),
and by most tumor-associated ECs, but not by normal
blood vessels.13 Inhibitory peptides and anti-integrin
monoclonal antibodies are currently being investigated in
solid tumors, with early evidence suggesting clinical ben-
efit in the use of an anti-avb3 antibody in colorectal cancer,
renal cell carcinoma, and melanoma. The recognition
sequence of the avb3 integrin is the RGD peptide on the b3
domain, and its most abundant ligands are components of
the extracellular matrix such as fibronectin, vitronectin, and
fibrinogen.14 Expression of integrin avb3 by ECs is stim-
ulated by angiogenic growth factors such as basic fibroblast
growth factor, tumor necrosis factor-a and interleukin-8,
and is upregulated not only in neoplastic tissue but also
during wound healing and inflammation.8 The HT29
colorectal cancer cell line used in the present experiment
was shown to express integrins avb5, avb6, and avb8.
15,16
The expression of human integrin avb3 is negligible on
HT29 tumor cells, but tumors express murine integrin avb3,
which is present on newly formed tumor vasculature in this
mouse model. Recently, several studies proved, with the
HT29 model, the relation between RGD-based radiotracer
uptake in tumors and the expression levels of both human
integrin avb3 and murine integrin avb3.
17,18 In our study,
the HT29 model allowed us to focus directly on tumor-
associated angiogenesis (TAA) via this novel avb3 inte-
grin-specific molecular tracer (P1227).
The utility of MRI-based molecular imaging is ham-
pered by its low sensitivity to visualize epitopes, which are
often present in the nanomolar range. Therefore, efforts
have been directed towards the combination of the target-
specific molecule with a large (super)paramagnetic pay-
load. Several authors have used RGD-coupled liposomes
containing Gd–DTPA to visualize tumor angiogenesis.19,20
Others have used RGD-labeled ultrasmall superparamag-
netic iron oxide nanoparticles (USPIO) and T2-weighted
imaging.21–23 Several disadvantages are associated with the
use of these large carriers. First, since they are exclusively
limited to the vascular compartment, binding sites on the
tumor cells and extracellular matrix will be out of reach.24
Second, endocytosis of the Gd-labeled liposomes may lead
to ‘quenching’ of the MRI signal. Third, concerns have
risen regarding the safety and biological side effects of
USPIOs in early clinical trials, although these were usually
mild and reversible.25 Finally, the pharmacokinetic prop-
erties of nano-sized tracers, including a plasma half-life of
several hours and retention by the reticuloendothelial sys-
tem better suit therapeutic than diagnostic purposes.
Here, we report for the first time the use of a low MW
tracer (1297 Da, diameter of 1–2 nm) consisting of a rou-
tinely used monogadolinated CA linked to an RGD peptide
as a tool to image TAA. The results demonstrate that,
compared with non-targeted DOTA (MW = 558 Da),
P1227 better discriminates angiogenic tumor tissue from
normal muscle. Gd–DOTA pools immediately in the blood,
as both SI in the tumor rim and muscle are high, whereas
P1227
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FIG. 3 NER of the tumor rim over time following administration of
DOTA or P1227 with or without pretreatment with cilengitide. Bars
standard error of the mean. NER normalized enhanced ratio, Gd–
DOTA gadolinium-tetraazacyclododecane tetraacetic acid
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P1227 does not change SI in muscle. Furthermore, aspe-
cific accumulation of Gd–DOTA in the well vascularized
oedemateous tumor tissue leads to persistent high NERs,
even after 225 min. At this point, SI in normal muscle
tissue did return to baseline, indicating that the high SI of
the tumor rim is due to extravasated Gd–DOTA tracer. This
may be explained by the higher MW of P1227, which
limits diffusion across normal and leaking tumoral micro-
vessel linings. Retention of the tracer due to specific
binding to the target integrin was demonstrated by the near
complete disappearance of P1227-induced tumor
enhancement after pretreatment with cilengitide. Cilengi-
tide is a known inhibitor of the integrins avb3, avb5, and
a5b1, but blocking the other integrins is not interfering with
the imaging result of HT29 tumors as P1227 was designed
to have only specificity for the RGD sequence on the b3
domain of the avb3 integrin. Compared with nanoparticle
imaging, the peak in signal enhancement after injecting
P1227 occurs much earlier (after 5 min). Sipkins et al.,26
who used an avb3-targeting antibody conjugated para-
magnetic liposome to image tumor angiogenesis in a rabbit
model, noted specific enhancement of angiogenic areas
after a time window of 24 h. Similarly, Winter et al.,19 who
used an integrin-directed nanoparticle with a size of
*70 nm, observed steadily increasing SI in the experi-
mental tumor model until the completion of the imaging
after 120 min. The relatively low accumulation of the
tracer in the present model may be explained by the smaller
size of the agent and by low internalization by HT29 cells,
as demonstrated in vitro by Bloch et al.27 This HT29 tumor
cell line, is known to express little amounts of integrin
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FIG. 4 Protein expression measured by western blot of av chains and b3 chains (a, d). Bars standard deviation. Representative avb3 integrin
immunohistology of the tumor rim (b) and tumor center (c). Scale bar 100 lm. * p B 0.05
TABLE 1 Correlation between histology and imaging parameters
(normalized enhancement ratio of the tumor rim)
5 min 20 min 35 min 50 min 65 min 80 min
avb3 integrin
DOTA 0.7 0.92 0.88 0.36 0.72 0.06
P1227 0.43 0.39 0.019 0.0092 0.046 0.35
Microvessel density
DOTA 0.52 0.63 0.99 0.9 0.59 0.86
P1227 0.44 0.69 0.57 0.49 0.67 0.47
Numbers indicate p values from Pearson correlation analysis
DOTA tetraazacyclododecane tetraacetic acid
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avb3.
15 Radiolabeled cyclic RGD peptides specifically
accumulate in avb3-expressing tumors by higher probe
internalization, and increases when cyclic peptides are
polymerized.28,29
The specificity of the novel tracer for avb3 integrin was
further demonstrated by the correlation between immuno-
histochemical staining and the observed MRI
enhancement. No statistically significant correlation was
noted with MVD, yet the Factor VIII staining method used
does not allow to distinguish proliferating, active ECs from
resting microvessel linings.
Several limitations apply to the interpretation of the
present results. First, although immunohistochemistry of
integrin chain expression can be regarded as a valid surro-
gate marker of active angiogenesis, no golden standard is
available at present. Correlation of MR imaging with in vivo
microscopic imaging of fluorescently-labelled tracers may
hold promise in this regard.30 Second, although expression
of avb3 integrin is generally low in healthy tissue, it is
known to be expressed by several other cell types (epithelial
cells, fibroblasts, smooth muscle cells) and to be implicated
in other conditions, including arterial stenosis.31 An addi-
tional tumor model with different integrin expression level
to demonstrate the ability of the probe would be interesting
to discriminate tissues with different expression levels.
Also, although the human HT29 is commonly used in
colorectal cancer research, the representativeness of a
xenograft model for the clinical situation remains partly
uncertain. Finally, it may be envisaged that compared with
nanoparticles with a high Gd payload, the sensitivity of the
current tracer for detecting small lesions is limited. This may
also explain the fact that we did not find a significant cor-
relation between imaging parameters and MVD.
CONCLUSIONS
We have shown that molecular MRI using a small
monogadolinated tracer targeting avb3 integrin holds
promise in safely and non-invasively assessing colorectal
tumor angiogenesis. Future work will include assessment
of anti-angiogenic therapy effects using this novel tracer.
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